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Abstract
Today, there are at least a dozen different genetic disorders caused by mutations within the LMNA gene, and collectively,
they are named laminopathies. Interestingly, the same mutation can cause phenotypes with different severities or even
different disorders and might, in some cases, be asymptomatic. We hypothesized that one possible contributing mechanism
for this phenotypic variability could be the existence of high and low expressing alleles in the LMNA locus. To investigate
this hypothesis, we developed an allele-specific absolute quantification method for lamin A and lamin C transcripts using
the polymorphic rs4641
C/T LMNA coding SNP. The contribution of each allele to the total transcript level was investigated in
nine informative human primary dermal fibroblast cultures from Hutchinson-Gilford progeria syndrome (HGPS) and
unaffected controls. Our results show differential expression of the two alleles. The C allele is more frequently expressed and
accounts for ,70% of the lamin A and lamin C transcripts. Analysis of samples from six patients with Hutchinson-Gilford
progeria syndrome showed that the c.1824C.T, p.G608G mutation is located in both the C and the T allele, which might
account for the variability in phenotype seen among HGPS patients. Our method should be useful for further studies of
human samples with mutations in the LMNA gene and to increase the understanding of the link between genotype and
phenotype in laminopathies.
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Introduction
Mutations in the LMNA gene are responsible for a broad range
of phenotypically distinct disorders called laminopathies. The
diseases are often subclassified into lipodystrophies, muscular
dystrophies, neuropathies, and premature aging syndromes [1].
The LMNA gene is located on chromosome 1q21.1–21.2 and
comprises 12 exons [2,3]. It encodes five A-type lamins (A, AD10,
AD150, C, and C2) produced by alternative splicing. Lamin A and
lamin C correspond to the 2 major lamin isoforms, and lamin C
has the highest expressed transcript [4]. Lamin A is encoded by
exons 1–12, while lamin C is encoded by exons 1–10 and possesses
five unique basic amino acid residues at its C-terminus. Lamin C2
is identical to Lamin C, except that it is encoded by an alternative
exon 1 located in the first intron of the LMNA gene. Lamin C2 has
only been described in mice and human germ cells [5,6]. Lamin
AD10 is identical to lamin A but has no exon 10 and has been
described in cancer cells [7]. Lamin AD150 is the isoform that has
been associated with HGPS and is only expressed at very low
levels in normal cells [1,4,8].
Different mutations in the LMNA gene can cause the same type
of disorder, but more interestingly, the same base substitution can
cause different disorders. One example is the c.1824C.T,
p.G608G mutation. This mutation in exon 11 of the LMNA gene
causes the segmental premature aging disease HGPS or the more
severe lethal skin disease restrictive dermopathy [9]. Another
example is the c.1930C.T, p.R644C mutation responsible for a
very high phenotypic variability between individuals [10]. LMNA
mutations sometimes also result in disorders that present several
overlapping and different phenotypic syndromes of varying
severities, e.g., Emery-Dreifuss muscular dystrophy, lipodystrophy
and cardiac conduction abnormalities [11]. In some cases,
individuals with LMNA mutations are asymptomatic [10,12]. This
variability provides evidence for mechanisms, in addition to the
specific LMNA mutation, that would influence the phenotypic
outcome, and it highlights the importance of the genetic
background for the development of an inherited disease.
Differential allelic expression has been estimated to affect 20–
50% of genes in humans [13,14]. Therefore, one possible
contributing mechanism for the phenotypic variability in lamino-
pathies could be the existence of low and high expressing alleles in
the LMNA locus. In this study, we addressed this hypothesis and
developed allele-specific absolute quantification assays.
Analysis and Results
Ethics Statement: All samples were obtained from cell
repositories and were therefore exempt from ethical approval
from our institutional review board.
Allele-specific absolute quantification assays make use of one of
the very few available coding SNPs in the LMNA gene, rs4641
C/T,
located in exon 10 and included in the lamin A, lamin AD150,
Lamin C2 and lamin C transcripts. Even though the assays cross-
react with minor isoforms, we have only referred to the major
isoforms, the lamin A and C transcripts, throughout the study.
Our quantification method used real-time RT-PCR technology
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Absolute quantification was obtained by comparison to a standard
curve of plasmids that contained the amplification products for the
different allele-specific transcript assays. Our quantitative, allele-
specific TaqMan assays measured the relative contribution of each
allele to the total amount of the LMNA transcripts, lamin A and
lamin C. Using this assay in combination with cloned standards for
the different transcript assays, we quantified the absolute transcript
copy number in 11 primary dermal fibroblast cultures corre-
sponding to 8 different individuals genotyped for rs4641
C/T:4
HGPS patients (AG01972B and GM01972B, AG11498 and
AG11498A, AG03513E, AG06917A and AG06917B) with a
confirmed c.1824C.T, p.G608G mutation and 4 unaffected
controls (AG03257, AG03258, AG03512 and AG06299B). All cell
cultures except for AG03258 and AG03512 were heterozygous
(C/T) for rs4641.
The AG03258 sample was homozygous for the C allele, and
sample AG03512 was homozygous for the T allele. These samples
were used as controls for the specificity of the allele-specific
TaqMan assays.
Cell culture, RNA isolation and cDNA synthesis were
performed as described previously [4]. TaqMan assay primers
and minor groove binder (MGB) probe sets for each allele-specific
assay were designed using Primer Express software version 2.0
(Applied Biosystems) and Primer 3 [15]. At least one primer per
assay was designed to cover an exon-exon boundary, and the
location of primer and probes are illustrated in Fig. 1A. Primer
and probe sequences for the different assays can be found in the
legend to Fig. 1. The different TaqMan assays and the size of the
amplification products are shown in Fig. 1B. Preparation of
standard curves of plasmids for each assay, real-time PCR
conditions, normalization and data analysis were performed as
described previously [4]. Representative standard curves for
absolute quantification of lamin C transcripts with the C and T
allele are shown in Fig. 1C. The absolute values of the transcript
copy numbers for each allele-specific assay were normalized to b-
glucoronidase. Normalized mean transcript levels from different
batches of cell cultures were averaged to a mean value per cell
culture. The relative transcript frequencies for each allele and
culture were obtained by dividing the amount of transcript from
each allele to the total amount of transcripts from both alleles for
lamin A and for lamin C (Fig. 2A–B). Finally, the mean transcript
frequency for each allele across all informative heterozygous cell
cultures was calculated for LMNA transcripts lamin A and lamin C
(Fig. 2C). The relative transcript frequencies for each allele
between informative cell cultures did not vary significantly from
each other. For the C allele, they ranged from 0.65 to 0.77 for the
lamin A transcript (Fig. 2A) and from 0.61 to 0.77 for the lamin C
transcript (Fig. 2B). Accordingly, the transcript frequencies for the
T allele ranged from 0.23 to 0.35 and from 0.23 to 0.34 for
transcripts lamin A and lamin C, respectively (Fig. 2A–B). The
frequency of the transcripts for the homozygous control sample for
the C allele was close to 1 for both transcripts (0.9995 for lamin A
and 0.9993 for lamin C). A similar situation was observed for the
homozygous control sample for the T allele, which had a
transcript frequency close to 1 for the lamin A transcript (0.947)
and for the lamin C transcript (0.991), indicating high allele-
specific specificity for the TaqMan assays (Fig. 2A–B). For the
lamin A transcript, the mean proportion of the contribution of
each allele to the total amount of transcript across all of the
heterozygote samples was 72%6SD 4% for allele C and
27%6SD 4% for allele T (Fig. 2C). For lamin C, the mean
proportion of the contribution of each allele to the total amount of
transcript across all heterozygote samples was 69%6SD 5% for
Figure 1. TaqMan assays for allele-specific absolute quantifica-
tion of the LMNA transcripts lamin A and lamin C. (A) Schematic
illustration of the location, in the39 endof the lamin A andlamin C cDNA,
of the primers and probes used in the different assays. The rs4641 SNP is
located in the last nucleotide of exon 10, which is present in lamin A and
lamin C transcripts. The forward primer, 59-CAACTCCACTGGGGAA-
GAAGTG-39 (orange arrows), and the TaqMan MGB probe, 59-ATGCG-
CAAGCTGGTG-39 (black bars), were the same in all 4 assays. Reverse
primers (blue and red arrows) make the assay specific for each allele and
transcript by allele-specific 39-end termination. The reverse primer in the
lamin A allele C assay was 59-GCTGCAGTGGGAGCCG-39 in the lamin A
allele T assay, 59-TGCTGCAGTGGGAGCCA-39 in the lamin C allele C assay,
59-GGCGGCTACCACTCACG-39, and in the lamin C allele T assay, 59-
CGGCGGCTACCACTCACA-39. Amplification of the lamin A and lamin C
transcripts also results in co-amplification of the lamin AD150 and lamin
C2, respectively. (B) Target transcripts and sizes of the PCR products of
the 4 designed TaqMan assays andthe endogenous control. (C) Standard
curves of plasmids containing the assay-specific amplicon, estimated
absolute copy numbers of transcript lamin C allele C (left) and transcript
lamin C allele T (right). A minimum of 5 standards (blue) ranging from
1.1610
1 to 1.1610
7 estimated copies of plasmids were used. Standards
and samples from 11 different human dermal fibroblast cultures (red).
Cultures were derived from 4 heterozygote HGPS patients (N=7),
heterozygote controls (N=2), and homozygote controls (N=2). Ct: cycle
threshold.
doi:10.1371/journal.pone.0025472.g001
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have high and low expressing alleles for the LMNA gene confirmed
by similar results in 2 different transcripts. The transcripts from the
C allele are more frequent and account for approximately 70% of
the total lamin A and lamin C transcripts compared to the lower
transcript frequency of approximately 30% from the T allele in all
heterozygote samples tested.
We further investigated the implications of whether the
localization of an LMNA mutation is present on a high or a low
expressing allele. For this purpose, we wanted to determine
whether the c.1824C.T, p.G608G mutation in classical HGPS
showed a preference for a specific allele. The genomic region of
the LMNA gene that contained the rs4641 SNP in exon 10 and the
c.1824C.T mutation in exon 11 was amplified using a high
fidelity enzyme and the following primers: 59-TGACGAGGAT-
GAGGATGGAGA-39 and 59-AGTTGCCCAGGAGGTAG-
GAG-39. The resulting PCR product was 1039 bp; it was
subsequently cloned into the pCR 2.1 Topo cloning vector
(Invitrogen), and the inserts were sequenced. Sequencing of the
exons 10–11 LMNA genomic DNA region showed that the HGPS
mutation was either located on the C allele (n=3; AG03506
(sample originated from the same donor as AG03513), AG06917,
and AG11498) or on the T allele (n=3; AG01972, HGALBV009,
and HGALBV011). The samples used for allele-specific transcript
quantification (AG03513, AG01972, AG06917 and AG11498),
were obtained from 4 skin biopsy donors. All four donors have
been described as patients that showed classical features of
progeria; however, no additional detailed information about the
Figure 2. Relative expressed allele frequencies of rs4641 alleles C and T for lamin A and C transcripts. (A, B) Human dermal fibroblast
cultures from 7 heterozygous cell cultures and 2 homozygous cell cultures. Estimated absolute copy numbers of the lamin A (A) and lamin C (B)
transcripts were normalized to the endogenous control b-glucoronidase. The mean value from different batches of the same cell culture is presented.
Mean value of AG11498 and AG11498A is presented as AG11498. Mean value of AG06917A and AG06917B is presented as AG06917. AG01972B and
GM01972B correspond to different biopsies from the same patient. Quantification of the homozygous control samples (AG03258 and AG03512)
showed only weak amplification with the C assay and no amplification with the T assay in the absence of the respective alleles. (C) Mean and standard
deviation of the frequencies of lamin A and lamin C transcripts for each allele across the 7 heterozygous human dermal fibroblast cultures derived
from 6 different individuals. Two-tailed unpaired t-test. Asterisks represent significant differences: ***P,0.0001.
doi:10.1371/journal.pone.0025472.g002
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difficult to relate our results to disease severity (Coriell Cell
Repositories, Camden NJ). Two samples, HGALBV009 and
HGALBV011, were obtained from the Progeria Research
Foundation. In these samples, the mutation was located on the
T allele, and the patients from whom they were taken have all of
the classical features of Hutchinson-Gilford progeria syndrome;
however, these patients were graded as less severe because neither
child had heart attacks or strokes by the ages of 14 years, and both
grew to above the 95%ile for height of a child with HGPS (yet still
below the 3%ile in height for age matched controls) (Dr. Leslie
Gordon, 2011, The Progeria Research Foundation Medical and
Research Database, Center for Gerontology and Healthcare
Research, Brown University, USA). This possible correlation
might suggest that if the HGPS mutation is located on the T allele,
it can result in a less severe phenotype.
Discussion
Other studies have related phenotype severity in HGPS to the
increased expression of progerin and an increased ratio of progerin
to lamin A in the more severe HGPS patients [16,17]. To test
whether the progerin transcript levels were higher when the
mutation was located on the C allele compared to the T allele, we
reviewed our earlier study in which we quantified the absolute
copy number of LMNA transcripts lamin A, lamin C and the
progerin transcript, lamin AD150 [4]. In that study, we found
variable but increasing amounts of the progerin transcript with
passage number of cells from HGPS patients [4]. However, we did
not see any indication that there was a correlation between the
expression of progerin and the allelic location of the mutation
(data not shown). The progerin/lamin A ratio was 1.0 for
AG06917 and 0.9 for AG11498. In both of these cell lines, the
mutation is located in the C allele. For sample AG01972, in which
the c.1824C.T mutation is located on the less frequently
expressed T allele, the progerin/lamin A ratio was slightly lower,
0.8 (data not shown). This observation is interesting, but further
investigations on additional samples and on specific mechanisms
are needed. An important focus for future studies will be to
determine if there is a correlation between the allele-specific
location of different LMNA mutations and the severity and
development of the clinical phenotype.
There have been other explanations raised to try to explain the
phenotypic variance among the laminopathies [10,18]. These
explanations include digenic inheritance, with a second mutation
that still remains to be identified in the LMNA gene, the
ZMPSTE24 gene or any other gene. There are also reports
suggesting that some of the laminopathies are better described as
intermediate syndromes because the patients have additional
clinical features that are less related to laminopathies [10,18].
In this study, we have developed an allele-specific assay for the
LMNA gene and showed that there is differential allelic expression
of this gene. Whether the different expression of the two alleles
might be caused by the rs4641 variant or a second variant, possibly
in the promotor or enhancer region, located in the same haplotype
block, remains to be investigated. Our allele-specific absolute
quantification method is useful for further studies on laminopa-
thies and presents the possibility of investigating whether
differential allelic expression can explain the very high phenotype
variability that is associated with these diseases and whether this
can be used to predict phenotypic severity.
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